Medicare PBM rebate ban could migrate to private sector

The Trump administration’s proposed rule barring drug companies from paying rebates to PBMs and drug plans for Part D Medicare could also affect commercial payers, HHS Secretary Alex Azar said Friday.

The proposed rule

Read the full 337 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE